---
layout: default
title: Aluminum Oxide Arsenic Trioxide Atropa Belladonna 
parent: 僅模型預測 (L5)
nav_order: 274
evidence_level: L5
indication_count: 0
---

# Aluminum Oxide Arsenic Trioxide Atropa Belladonna 
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-ingredient Homeopathic Complex (25 Components): Insufficient Data for TxGNN Repurposing Analysis

## One-Sentence Summary

This product is a 25-component homeopathic combination containing botanical extracts, minerals, and biological nosodes (including Echinacea, Arsenic Trioxide, Atropa Belladonna, and Measles Virus), with no registered indications on record.
The TxGNN model was **unable to generate any repurposing predictions** for this candidate, as no DrugBank ID could be mapped and no original indication exists to anchor the analysis.
With **0 clinical trials** and **0 supporting publications** identified in this pipeline, this candidate cannot proceed under the current framework.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No registered indication available |
| Predicted New Indication | Unable to generate — no DrugBank mapping |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no predictions generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This candidate is not a single molecular entity but a **heterogeneous 25-component homeopathic mixture** comprising:

- **Botanical extracts**: Echinacea angustifolia, Atropa belladonna, Goldenseal (Hydrastis canadensis), Matricaria recutita, Milk thistle, Taraxacum officinale, Chelidonium majus, Baptisia tinctoria, Ledum palustre, Thuja occidentalis, Phytolacca americana, Peumus boldus
- **Minerals / inorganics**: Aluminum oxide, Arsenic trioxide, Silicon dioxide, Sulfur, Mercurius solubilis, Oyster shell calcium carbonate
- **Biological nosodes**: Human sputum (Bordetella pertussis-infected), Measles virus, Thyroid (unspecified), Rancid beef, Egg phospholipids
- **Plant spores**: Lycopodium clavatum, Toxicodendron pubescens

The TxGNN knowledge graph operates on discrete drug nodes identified by DrugBank IDs. Because this product has **no DrugBank ID** (`drugbank_id: null`) and cannot be mapped to any single pharmacological entity in the knowledge graph, the model returned zero predictions. This is expected behavior, not a pipeline failure.

Additionally, because the product is not marketed in any jurisdiction covered by this system (Taiwan FDA: 未上市, NDA count: 0), there is no regulatory anchor for original indication inference.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on Arsenic Trioxide**: When present as a conventional pharmaceutical agent (e.g., Trisenox®), arsenic trioxide carries black box warnings for QT prolongation, APL differentiation syndrome, and cardiomyopathy. If this product is intended for non-homeopathic use at pharmacological doses, safety review must begin with arsenic trioxide labeling requirements.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate is a multi-ingredient homeopathic complex that cannot be represented as a single node in the TxGNN knowledge graph, producing zero repurposing predictions. Without a DrugBank ID, original indication, or any regulatory approval, the standard repurposing evaluation pipeline cannot proceed.

**To proceed, the following is needed:**

- **Identity clarification**: Determine whether this is a registered homeopathic product with an NHN/NDC number; if so, retrieve the product monograph to confirm intended indication and ingredient dilutions
- **Component-level analysis**: If the intent is to evaluate a specific active ingredient (e.g., Arsenic trioxide as a conventional oncology agent), submit that single INN as a separate candidate with its own DrugBank ID
- **DrugBank mapping**: Resolve `drugbank_id: null` — attempt mapping via individual ingredient names or product-level registry cross-reference
- **MOA documentation** (Data Gap DG002): Without mechanism of action data, mechanistic plausibility for any indication cannot be assessed
- **Regulatory review** (Data Gap DG001): TFDA package insert or equivalent labeling must be located before any safety evaluation can begin
- **Scope decision**: Clarify whether the goal is to evaluate the **mixture as a whole** or **individual components** — these require fundamentally different analytical frameworks
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

